{"transactions":[{"id":4105,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:17.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001935668-26-000002","document":"form4-09042026_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935668/000193566826000002/form4-09042026_060909.xml","form_type":"4"}},{"id":4104,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:17.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001935668-26-000002","document":"form4-09042026_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935668/000193566826000002/form4-09042026_060909.xml","form_type":"4"}},{"id":1048608,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:18.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 23, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023703","document":"form4-09042025_050907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023703/form4-09042025_050907.xml","form_type":"4"}},{"id":1048607,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:18.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023703","document":"form4-09042025_050907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023703/form4-09042025_050907.xml","form_type":"4"}},{"id":1768752,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T21:00:50.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032 and (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013899","document":"form4-10032023_051016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013899/form4-10032023_051016.xml","form_type":"4"}},{"id":2162621,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:04:40.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032."}],"balance_after":10000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-22-098956","document":"tm2225460-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098956/tm2225460-10_4seq1.xml","form_type":"4"}},{"id":2215582,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-07-05T20:32:55.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":1.09,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-077380","document":"tm2220369-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922077380/tm2220369-1_4seq1.xml","form_type":"4"}}]}